Genomic landscape of ERBB3 alterations in metastatic solid tumours: a real-world data analysis.
A genetic change in some metastatic cancers predicts worse outcomes, potentially helping doctors tailor treatment intensity.
PATIENTS AND METHODS, We analysed real-world data from 5416 patients with metastatic solid tumours who underwent next-generation sequencing. The ERBB3 mutation status was not prognostic (adjusted hazard ratio [HR] 0,97, P = 0,52), whereas ERBB3 amplification was independently associated with a worse OS (HR 1,43, P = 0,024).
What the study was
- Study design
- Real-world genomic cohort analysis
- Population
- PATIENTS
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- ESMO open
Why it surfaced
Abstract-reviewed real-world genomic cohort analysis scored conservatively for genomics/precision medicine; 7/10 reflects the available design, relevance, novelty, and population or unmet-need evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.